Clinical characteristics and sick leave associated with infectious mononucleosis in a real-world setting in Germany

被引:6
|
作者
Kap, Elisabeth J. [1 ]
Konrad, Marcel [2 ]
Kostev, Karel [1 ]
机构
[1] IQVIA, Frankfurt, Germany
[2] FOM Univ Appl Sci Econ & Management, Frankfurt, Germany
关键词
CHRONIC-FATIGUE-SYNDROME; PREDICTORS;
D O I
10.1111/ijcp.14690
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Infectious mononucleosis (IM), mainly caused by the Epstein-Barr virus, can result in prolonged symptoms. The objective of this study was to look at the length of sick leave, diagnosis of IM, treatment and comorbidities in a real-world setting in Germany. Methods: This retrospective, cross-sectional study used electronic medical record data from office-based practices in Germany and included patients with an initial confirmed diagnosis of IM between the 1 January 1 2016 and December 31 2018. Patients of working age (18-65 years) with statutory health insurance were included in order to look at the working population who would need a sick note for their employers in case of illness. Results: Epstein-Barr virus was the most common cause of IM in this population of 1,596 patients with an average age of 32 years. The majority of patients were women in all cohorts (similar to 60%). Although CFS, myocarditis and thrombocytopenia were not recorded frequently around the index date, the occurrence did increase during the follow-up period. Around half of patients received antibiotics. About 62% of all patients were on sick leave for an average of 20 calendar days around the time of their IM diagnosis. Only 1% were still on sick leave after 6 months. Conclusions: A small percentage of patients remained on continuous sick leave after 6 months, suggesting that the long-term effect of IM on the ability to work was minor in our cohort. However, patients could still be experiencing symptoms that influence their quality of life.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Insulin thermostability in a real-world setting
    Pendsey, Sanket
    James, Steven
    Garrett, Timothy J.
    Nord, Anders Bay
    Pendsey, Sharad
    Malmodin, Daniel
    Karlsson, Goran
    Maniam, Jayanthi
    Atkinson, Mark A.
    Forsander, Gun
    Ogle, Graham D.
    LANCET DIABETES & ENDOCRINOLOGY, 2023, 11 (05): : 310 - 312
  • [32] Clinical treatment of chronic and episodic migraine with onabotulinumtoxinA in a real-world setting
    Velasco-Juanes F.
    Gómez-Esteban J.C.
    Fernández-Valle T.
    Matute-Nieves A.
    Almeida-Velasco J.
    Lloret-Villas M.I.
    Ugarriza-Serrano I.
    Drugs & Therapy Perspectives, 2018, 34 (7) : 335 - 343
  • [33] Haemophilia in a real-world setting: the value of clinical experience in data collection
    Dolan, Gerry
    Iorio, Alfonso
    Jokela, Vuokko
    Juusola, Kristian
    Lassila, Riitta
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 96 : 3 - 9
  • [34] Safety and Tolerability of Dimethyl Fumarate in Japanese Real-world Clinical Setting
    Fukazawa, T.
    Yamamura, T.
    Ochi, H.
    Sato, R.
    Makioka, H.
    Sato, Y.
    Onizuka, Y.
    Matsuda, N.
    Torii, S.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP59 - NP59
  • [35] Optimizing Read Depth of Real-World Sequencing Data in a Clinical Setting
    Wu, F.
    Chu, J.
    Schell, R.
    Jung, S.
    Diaz, F. Lopez
    Mayer, J.
    Rivera, S.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2023, 25 (11): : S100 - S100
  • [36] Teaching innovations at McGill prepare students for real-world clinical setting
    McDonagh, Patrick
    JOURNAL OF THE CANADIAN DENTAL ASSOCIATION, 2008, 74 (07): : 602 - 604
  • [37] "Real-world" eligibility for aducanumab depends on clinical setting and patients' journey
    Padovani, Alessandro
    Caratozzolo, Salvatore
    Rozzini, Luca
    Pilotto, Andrea
    Benussi, Alberto
    Tedeschi, Gioacchino
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2022, 70 (02) : 626 - 628
  • [38] Clinical efficacy and safety of secukinumab for psoriasis in a real-world setting in Turkey
    Yildirim, Fatma Elif
    Hapa, Fatma Asli
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) : 1531 - 1537
  • [39] Motives for quetiapine discontinuation in real-world clinical setting: a retrospective review
    Parise, V. Fricchione
    Addeo, L.
    Laezza, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S528 - S529
  • [40] Long-term persistence with mirabegron in a real-world clinical setting
    Wada, Naoki
    Watanabe, Masaki
    Banjo, Hiroko
    Tsuchida, Miyu
    Hori, Junichi
    Tamaki, Gaku
    Azumi, Makoto
    Kita, Masafumi
    Kakizaki, Hidehiro
    INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 (05) : 501 - 506